ECSP23018458A - Proteínas de unión restringidas activadas de forma condicional - Google Patents

Proteínas de unión restringidas activadas de forma condicional

Info

Publication number
ECSP23018458A
ECSP23018458A ECSENADI202318458A ECDI202318458A ECSP23018458A EC SP23018458 A ECSP23018458 A EC SP23018458A EC SENADI202318458 A ECSENADI202318458 A EC SENADI202318458A EC DI202318458 A ECDI202318458 A EC DI202318458A EC SP23018458 A ECSP23018458 A EC SP23018458A
Authority
EC
Ecuador
Prior art keywords
tumor
binding proteins
conditionally activated
constructs
restricted binding
Prior art date
Application number
ECSENADI202318458A
Other languages
English (en)
Inventor
Tseng-Hui Chen
Jeremiah Degenhardt
Chad May
Patricia Culp
Danielle Dettling
Robert B Dubridge
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP23018458A publication Critical patent/ECSP23018458A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a construcciones de activación redirigida biespecífica condicional, o COBRA, que se administran en un formato de profármaco activo. Tras la exposición a las proteasas tumorales, las construcciones se escinden y activan, de modo que pueden unirse a uno o más antígenos diana tumorales (TTA), así como a CD3, reclutando así linfocitos T que expresan CD3 en el tumor, lo que da como resultado el tratamiento. En algunas modalidades, el antígeno diana del tumor incluye B7H3, CA9 (CAIX), EGFR, EpCAM, FOLR1, HER2, LyPD3, y/o Trop2.
ECSENADI202318458A 2020-08-17 2023-03-16 Proteínas de unión restringidas activadas de forma condicional ECSP23018458A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063066565P 2020-08-17 2020-08-17

Publications (1)

Publication Number Publication Date
ECSP23018458A true ECSP23018458A (es) 2023-04-28

Family

ID=77655705

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202318458A ECSP23018458A (es) 2020-08-17 2023-03-16 Proteínas de unión restringidas activadas de forma condicional

Country Status (16)

Country Link
US (1) US20240026011A1 (es)
EP (1) EP4196503A2 (es)
JP (1) JP2023538366A (es)
KR (1) KR20230048146A (es)
CN (1) CN116419925A (es)
AR (1) AR123266A1 (es)
AU (1) AU2021329290A1 (es)
CA (1) CA3191431A1 (es)
CL (1) CL2023000477A1 (es)
CO (1) CO2023002164A2 (es)
EC (1) ECSP23018458A (es)
IL (1) IL300598A (es)
MX (1) MX2023002002A (es)
PE (1) PE20230856A1 (es)
TW (1) TW202214707A (es)
WO (1) WO2022040128A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR128593A1 (es) * 2022-02-23 2024-05-22 Takeda Pharmaceuticals Co Proteínas de unión condicionalmente biespecíficas
WO2024040228A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding proteins
WO2024040220A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding fusion proteins
WO2024147897A2 (en) * 2023-01-05 2024-07-11 Harpoon Therapeutics, Inc. Trop2 targeting trispecific protein for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027160B1 (ru) 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
WO2017156178A1 (en) 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Inducible binding proteins and methods of use
IL302613A (en) * 2017-09-08 2023-07-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
CN114390938A (zh) 2019-03-05 2022-04-22 武田药品工业有限公司 受约束的条件性活化的结合蛋白

Also Published As

Publication number Publication date
US20240026011A1 (en) 2024-01-25
IL300598A (en) 2023-04-01
EP4196503A2 (en) 2023-06-21
WO2022040128A3 (en) 2022-04-07
CL2023000477A1 (es) 2023-11-10
CN116419925A (zh) 2023-07-11
JP2023538366A (ja) 2023-09-07
MX2023002002A (es) 2023-07-06
WO2022040128A2 (en) 2022-02-24
PE20230856A1 (es) 2023-05-29
CA3191431A1 (en) 2022-02-24
CO2023002164A2 (es) 2023-03-07
TW202214707A (zh) 2022-04-16
KR20230048146A (ko) 2023-04-10
AU2021329290A1 (en) 2023-04-13
AR123266A1 (es) 2022-11-16

Similar Documents

Publication Publication Date Title
ECSP23018458A (es) Proteínas de unión restringidas activadas de forma condicional
CL2021002242A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
CY1123858T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
CY1125429T1 (el) Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης
CY1121148T1 (el) Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
PE20170585A1 (es) Moleculas de union a antigeno biespecificas activadoras de celulas t
CY1117922T1 (el) Her2/neu-eiδika αντισωματα και μεθοδοι χρησης αυτων
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
PE20141658A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
CY1123743T1 (el) Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου
GT201100223A (es) Proteínas de unión específicas y sus usos
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
CO2023009342A2 (es) Proteínas de unión condicionalmente biespecíficas
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
UY39416A (es) Moléculas de direccionamiento inmunes multiespecíficas y usos de estas
EA201992278A1 (ru) Способы и композиции для снижения иммуногенности
MX2022005330A (es) Moleculas de union multiespecificas con scfv en el extremo nterminal.
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
CO2023014772A2 (es) Métodos terapéuticos que usan proteínas de unión activadas condicionalmente restringidas